account_balance
Investment manager · 13F filer · SEC CIK 1940272
Adar1 Capital Management, LLC
Reported value$2.13Bas of Jun 30, 2026
Positions267 44 new, 71 sold out
Top 10 weight41.9%ABVX alone is 11%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ABVXAbivax SA
11.3%Added +29%
PTGXProtagonist Therapeutics Inc
5.5%Trimmed −3%
ROIVRoivant Sciences Ltd
5.3%Trimmed −4%
SPYState STR SPDR S&P 500 ETF T
4.5%Added +70%
IMVTImmunovant Inc
4.2%Trimmed −13%
ZLABZai Lab Ltd
3.0%Added +136%
AGIOAgios Pharmaceuticals Inc
2.2%Added +816%
CRNXCrinetics Pharmaceuticals In
2.1%Added +7%
BOXXEa Series Trust
1.9%
CYTKCytokinetics Inc
1.8%Trimmed −28%
SEPNSepterna Inc
1.5%Trimmed −14%
AVRAnteris Technologies Global
1.5%Trimmed −17%
ABVXAbivax SA
11.3%Added +29%
PTGX5.5%ROIV5.3%SPY4.5%IMVTImmunovant Inc
4.2%Trimmed −13%
ZLAB3.0%AGIO2.2%CRNX2.1%
BOXX1.9%
CYTK1.8%SEPN1.5%AVR1.5%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ABVX Abivax SA 11.3% Added +29%PTGX Protagonist Therapeutics Inc 5.5% Trimmed −3%ROIV Roivant Sciences Ltd 5.3% Trimmed −4%SPY State STR SPDR S&P 500 ETF T 4.5% Added +70%IMVT Immunovant Inc 4.2% Trimmed −13%ZLAB Zai Lab Ltd 3.0% Added +136%AGIO Agios Pharmaceuticals Inc 2.2% Added +816%
CRNX Crinetics Pharmaceuticals In 2.1% Added +7%
BOXX Ea Series Trust 1.9% Held
CYTK Cytokinetics Inc 1.8% Trimmed −28%SEPN Septerna Inc 1.5% Trimmed −14%AVR Anteris Technologies Global 1.5% Trimmed −17%What changed